Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

ActiveSite Pharmaceuticals, Inc., announced today the online publication of a study in the journal Diabetes that describes the effectiveness of its novel plasma kallikrein inhibitor ASP-440 in reducing blood-retinal barrier breakdown in a rodent model of diabetes.

28 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

Scientists reveal protein target that can trigger myocarditis

People with type 1 diabetes, whose insulin-producing cells have been destroyed by the body's own immune system, are particularly vulnerable to a form of inflammatory heart disease caused by a different autoimmune reaction.

24 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Statin drug may help prevent blindness in diabetics

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes.

17 Feb 2011

Early signs of cardiovascular disease manifest before onset of puberty in children with diabetes: Study

Cardiovascular disease is the leading cause of death in patients with diabetes. Patients with type 1diabetes have a 200 percent to 400 percent greater chance of developing cardiovascular disease than those without diabetes. Medical College of Wisconsin researchers at Children's Hospital of Wisconsin discovered the early signs of cardiovascular disease are likely to manifest before the onset of puberty in many children with diabetes.

15 Feb 2011

First 7 stem cell lines grown at UMMS Human Stem Cell Bank ready for global distribution

The first seven stem cell lines grown and banked at the University of Massachusetts Medical School's Human Stem Cell Bank are ready for worldwide distribution to researchers working on discovering new therapeutic treatments for diseases such as cancer, juvenile diabetes, Alzheimer's and Parkinson's, among others.

11 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Scientists create functioning human intestinal tissue from pluripotent stem cells

For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells.

13 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Merck plans to acquire SmartCells

Today pharmaceutical company, Merck & Co., Inc. announced it will acquire SmartCells, Inc., a private biotech developing a glucose-responsive insulin whose proof-of-concept preclinical trials were partially funded by the Juvenile Diabetes Research Foundation.

4 Dec 2010

Harvard researcher to receive 2010 Naomi Berrie Award from Columbia University Medical Center

Columbia University Medical Center will present the 2010 Naomi Berrie Award to a Harvard researcher who has made important advances in understanding the molecular basis for links between obesity, diabetes and heart disease. A promising young investigator at Columbia will also be recognized for her novel investigations regarding the basis for disordered lipid metabolism in diabetes.

20 Nov 2010

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Recommendations for safe and effective testing of artificial pancreas systems in real-life settings

Diabetes experts at a meeting convened by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) took the next step in advancing efforts toward the development of an artificial pancreas: putting forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations.

11 Nov 2010

Dietary intervention reduces emergence of diabetes-predictive autoantibodies by 50%

A Finnish study published in the November 11, 2010 issue of the New England Journal of Medicine confirms the hypothesis that infant feeding plays a role in the initiation of the disease process leading to type 1 diabetes in children carrying increased genetic disease risk.

11 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

Diabetes threatens the eyesight of many unsuspecting Americans

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam. As the number of people with Type 2 diabetes rises in the U.S., the CDC projects that the number of adults with diabetic retinopathy will double by the year 2050. Yet 90 percent of diabetic eye disease can be prevented simply by proper regular examinations and treatment and by controlling blood sugar.

27 Oct 2010

Human haptoglobin gene mutation increases risk of diabetic complications

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a multifactorial disease of complex etiology characterized by the autoimmune destruction of pancreatic beta cells. In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering disease, with virus infection having perhaps the strongest association.

27 Oct 2010

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

21 Oct 2010

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

Diabetes management accepted for coverage by Chemical Abstracts

Scientists reveal protein target that can trigger myocarditis

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Statin drug may help prevent blindness in diabetics

Early signs of cardiovascular disease manifest before onset of puberty in children with diabetes: Study

First 7 stem cell lines grown at UMMS Human Stem Cell Bank ready for global distribution

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Scientists create functioning human intestinal tissue from pluripotent stem cells

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Merck plans to acquire SmartCells

Harvard researcher to receive 2010 Naomi Berrie Award from Columbia University Medical Center

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Recommendations for safe and effective testing of artificial pancreas systems in real-life settings

Dietary intervention reduces emergence of diabetes-predictive autoantibodies by 50%

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Diabetes threatens the eyesight of many unsuspecting Americans

Human haptoglobin gene mutation increases risk of diabetic complications

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in